Role of Mineralocorticoid Receptors in Obstructive Sleep Apnea and Metabolic Syndrome

Overview

Journal Curr Hypertens Rep

Specialty Cardiology & Vascular Diseases

Date 2018 Mar 21

PMID 29556729

Citations 8

Authors

Badhma Valaiyapathi

David A Calhoun

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: This review will summarize recent developments in the research on the mineralocorticoid receptor and its impact on obstructive sleep apnea and metabolic syndrome.

Recent Findings: Aldosterone excess plays an important role in the association between resistant hypertension and obstructive sleep apnea. The prevalence of obesity is increasing rapidly worldwide and is especially common among patients with obstructive sleep apnea, resistant hypertension, and metabolic syndrome, suggesting probable mechanistic links between these three conditions. Mineralocorticoid receptor expression is increased in obese individuals, which may contribute to the common association between obesity and hyperaldosteronism. Mineralocorticoid receptor blockers reduce the severity of obstructive sleep apnea among resistant hypertension patients. A large body of literature demonstrates a strong association between obesity, hyperaldosteronism, resistant hypertension, and sleep apnea, including specific benefit of treatment with mineralocorticoid receptor blockers for these separate disorders.

Citing Articles

Obesity, aldosterone excess, and mineralocorticoid receptor activation: Parallel or intersected circumstances?.

Puzantian H, Townsend R, Bansal S J Clin Hypertens (Greenwich). 2024; 26(12):1384-1390.

PMID: 39584490 PMC: 11654859. DOI: 10.1111/jch.14898.

Does obstructive sleep apnea-induced intermittent hypoxia increase the incidence of solitary pulmonary nodules, thyroid nodules, and other disorders? A retrospective study based on 750 cardiovascular disease patients.

Ding C, Mao L, Lu Y, Wu S, Ji W Sleep Breath. 2024; 28(4):1553-1562.

PMID: 38627339 PMC: 11303425. DOI: 10.1007/s11325-024-03036-x.

Primary aldosteronism and obstructive sleep apnea: What do we know thus far?.

Loh H, Sukor N Front Endocrinol (Lausanne). 2022; 13:976979.

PMID: 36246876 PMC: 9556954. DOI: 10.3389/fendo.2022.976979.

The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial.

Neeland I, Eliasson B, Kasai T, Marx N, Zinman B, Inzucchi S Diabetes Care. 2020; 43(12):3007-3015.

PMID: 33004464 PMC: 7770278. DOI: 10.2337/dc20-1096.

A review of the "OMICS" for management of patients with obstructive sleep apnoea.

Conte L, Greco M, Toraldo D, Arigliani M, Maffia M, De Benedetto M Acta Otorhinolaryngol Ital. 2020; 40(3):164-172.

PMID: 32773777 PMC: 7416376. DOI: 10.14639/0392-100X-N0409.

References

Boggia J, Li Y, Thijs L, Hansen T, Kikuya M, Bjorklund-Bodegard K . Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet. 2007; 370(9594):1219-29. DOI: 10.1016/S0140-6736(07)61538-4. View

Luther J . Aldosterone in vascular and metabolic dysfunction. Curr Opin Nephrol Hypertens. 2015; 25(1):16-21. PMC: 4824306. DOI: 10.1097/MNH.0000000000000189. View

Bochud M, Nussberger J, Bovet P, Maillard M, Elston R, Paccaud F . Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension. 2006; 48(2):239-45. DOI: 10.1161/01.HYP.0000231338.41548.fc. View

Logan A, Perlikowski S, Mente A, Tisler A, Tkacova R, Niroumand M . High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens. 2001; 19(12):2271-7. DOI: 10.1097/00004872-200112000-00022. View

Pratt-Ubunama M, Nishizaka M, Boedefeld R, Cofield S, Harding S, Calhoun D . Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest. 2007; 131(2):453-9. DOI: 10.1378/chest.06-1442. View

Rocchini A, Katch V, Grekin R, Moorehead C, Anderson J . Role for aldosterone in blood pressure regulation of obese adolescents. Am J Cardiol. 1986; 57(8):613-8. DOI: 10.1016/0002-9149(86)90845-3. View

Barcelo A, Pierola J, Esquinas C, de la Pena M, Arque M, Alonso-Fernandez A . Relationship between aldosterone and the metabolic syndrome in patients with obstructive sleep apnea hypopnea syndrome: effect of continuous positive airway pressure treatment. PLoS One. 2014; 9(1):e84362. PMC: 3896347. DOI: 10.1371/journal.pone.0084362. View

Fallo F, Veglio F, Bertello C, Sonino N, Della Mea P, Ermani M . Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab. 2005; 91(2):454-9. DOI: 10.1210/jc.2005-1733. View

Dudenbostel T, Calhoun D . Resistant hypertension, obstructive sleep apnoea and aldosterone. J Hum Hypertens. 2011; 26(5):281-7. PMC: 3748801. DOI: 10.1038/jhh.2011.47. View

10.

Ke X, Guo W, Peng H, Hu C, Zhang H, Peng C . Association of aldosterone excess and apnea-hypopnea index in patients with resistant hypertension. Sci Rep. 2017; 7:45241. PMC: 5361120. DOI: 10.1038/srep45241. View

11.

Bixler E, Vgontzas A, Lin H, ten HAVE T, Leiby B, Vela-Bueno A . Association of hypertension and sleep-disordered breathing. Arch Intern Med. 2000; 160(15):2289-95. DOI: 10.1001/archinte.160.15.2289. View

12.

Garg R, Adler G . Aldosterone and the Mineralocorticoid Receptor: Risk Factors for Cardiometabolic Disorders. Curr Hypertens Rep. 2015; 17(7):52. DOI: 10.1007/s11906-015-0567-8. View

13.

Garg R, Kneen L, Williams G, Adler G . Effect of mineralocorticoid receptor antagonist on insulin resistance and endothelial function in obese subjects. Diabetes Obes Metab. 2013; 16(3):268-72. PMC: 3946356. DOI: 10.1111/dom.12224. View

14.

Pankow W, Nabe B, Lies A, Becker H, Kohler U, KOHL F . Influence of sleep apnea on 24-hour blood pressure. Chest. 1997; 112(5):1253-8. DOI: 10.1378/chest.112.5.1253. View

15.

Vogt B, Bochud M, Burnier M . The association of aldosterone with obesity-related hypertension and the metabolic syndrome. Semin Nephrol. 2007; 27(5):529-37. DOI: 10.1016/j.semnephrol.2007.07.009. View

16.

Vecchiola A, Lagos C, Carvajal C, Baudrand R, Fardella C . Aldosterone Production and Signaling Dysregulation in Obesity. Curr Hypertens Rep. 2016; 18(3):20. DOI: 10.1007/s11906-016-0626-9. View

17.

Levy P, Bonsignore M, Eckel J . Sleep, sleep-disordered breathing and metabolic consequences. Eur Respir J. 2009; 34(1):243-60. DOI: 10.1183/09031936.00166808. View

18.

Walia H, Li H, Rueschman M, Bhatt D, Patel S, Quan S . Association of severe obstructive sleep apnea and elevated blood pressure despite antihypertensive medication use. J Clin Sleep Med. 2014; 10(8):835-43. PMC: 4106935. DOI: 10.5664/jcsm.3946. View

19.

Ingelsson E, Pencina M, Tofler G, Benjamin E, Lanier K, Jacques P . Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation. 2007; 116(9):984-92. DOI: 10.1161/CIRCULATIONAHA.107.708537. View

20.

Tuck M, Sowers J, Dornfeld L, Kledzik G, Maxwell M . The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med. 1981; 304(16):930-3. DOI: 10.1056/NEJM198104163041602. View